# DAVITA INC. (DVA) FY2026 Q3 Revenue by Business Segment (4 categories)

- Company: DAVITA INC. (DVA)
- Statement: DAVITA INC. (DVA) FY2026 Q3 P&L / Income Statement, https://plicit.ai/financials/dva/fy2026-q3-income-statement
- Period: 2026-07-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0000927066-26-000134
- Page: https://plicit.ai/financials/dva/fy2026-q3-income-statement/revenue-by-business-segment-4-categories
- Chart image: https://plicit.ai/charts/dva-fy2026-q3-revenue-by-business-segment-4-categories-sankey.png

## Chart details: Revenue by Business Segment (4 categories)

Income statement for 2026-07-01 through 2026-09-30. View: Business segment (4 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 3,578,126,000 US dollars
- **Total operating expenses**: 3,078,871,000 US dollars
- **Operating income**: 499,255,000 US dollars
- **Other income (expense), net (calculated)**: negative 140,548,000 US dollars
- **Income before income taxes**: 358,707,000 US dollars
- **Income tax expense**: 89,318,000 US dollars
- **Net income**: 269,389,000 US dollars
- **U S Dialysis And Related Lab Services with Intersegment**: 3,050,478,000 US dollars
- **Other Operating Segments with Intersegment**: 551,766,000 US dollars
- **Patient care costs**: 2,451,047,000 US dollars
- **General and administrative**: 408,697,000 US dollars
- **Depreciation and amortization**: 165,188,000 US dollars
- **Equity investment income, net**: negative 8,237,000 US dollars
- **Goodwill and other asset impairment charges**: 62,176,000 US dollars
- **Revenue before reconciliation (calculated)**: 3,602,244,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **U. S. Dialysis And Related Lab Services - Intersegment Elimination**: negative 22,008,000 US dollars. Reported reconciliation to consolidated revenue.
- **Other Operating Segment - Intersegment Elimination**: negative 2,110,000 US dollars. Reported reconciliation to consolidated revenue.

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
- Of which attributable to DAVITA INC.: $222.93 M; to noncontrolling interests: $46.46 M.

## Key Takeaways

- Other operating segments supplied 61% of the $157.90 M rise in revenue from a year earlier.
- Counting internal sales, those segments grew 21% to $551.77 M; U.S. dialysis grew 2.4% to $3.05 B.
- Sales U.S. dialysis made to DaVita's own other units rose to $22.01 M from $11.93 M.
- U.S. dialysis still holds 87% of DaVita's $7.55 B of goodwill on September 30, 2026.

## The Unvarnished Truth

### Side businesses, 15% of DaVita's sales, delivered 61% of its growth

Strip out dialysis and DaVita's growth story looks very different. Its other operating segments, 15% of sales, supplied 61% of the $157.90 M rise in revenue from a year earlier. Counting sales to the rest of the group, they grew 21% to $551.77 M, while U.S. dialysis grew just 2.4%. Within those segments, revenue from sources other than patient care jumped to $163.01 M from $115.86 M. Yet the same segments posted an $18.64 M operating loss, dragged down by the $62.18 M write-down in China. Growth, in other words, arrived where the profits did not.

Why does dialysis sell inside its own group? U.S. dialysis booked $22.01 M of revenue from other DaVita segments this quarter, up from $11.93 M, and the group eliminates $24.12 M of such internal sales in total. The filing does not say which units were buying. What it does show is where the acquisition money sits: U.S. dialysis carries 87% of the $7.55 B of goodwill, while the other segments hold the China unit whose goodwill was just cut by $57.10 M. The segments that grow fastest are the ones carrying the write-down risk.

For investors, the filing describes a slow core and a fast, unprofitable fringe. The dialysis core grows slowly and pays the bills; the other segments grow fast but just lost money on paper. Management's own adjusted measure puts these segments' operating income at $44 million this quarter, down from $57 million in the quarter before. So even before the China charge, their profit shrank from the prior quarter. Watch whether integrated kidney care and the international clinics can turn their sales growth into steady profit. If the fastest-growing part of DaVita cannot earn money, what exactly is the growth worth?

## Intelligent Insights for Investors

### Which parts of DaVita's sales by business drove the change over the past year?

The other operating segments carried the growth, supplying 61% of the increase this quarter. Not everything rose: the deduction for U.S. dialysis sales made inside the group grew by $10.08 M.

### Which part of DaVita's sales by business grew fastest over the past year?

The other operating segments: up 21% this quarter, against 4.6% for revenue as a whole.

### How much does DaVita depend on the biggest piece of its sales by business?

Heavily: U.S. dialysis and related lab services brought in 85% of these sales this quarter, against 15% for the other operating segments.

## Intelligent Insights for Lenders

### Where is DaVita's acquisition goodwill concentrated across its divisions?

Mostly in U.S. dialysis: it carries 87% of the $7.55 B of goodwill from past acquisitions on DaVita's books on September 30, 2026.

## Intelligent Insights for Employees

### Which of DaVita's businesses brings in the most sales?

U.S. dialysis and related lab services carries the sales, with 85% this quarter. Next come the other operating segments, at 15%.

## Intelligent Insights for Everyone

### How has the mix of DaVita's sales by business shifted over the past year?

Toward the other operating segments: they made up 15% of revenue this quarter, against 13% a year earlier, while U.S. dialysis lost the most share.
